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76Objective: To determine the long-term outcomes of mitral valvuloplasty for myxomatous valve disease, rheu-
matic valve disease, and functional mitral regurgitation.
Methods: A total of 1503 patients underwent mitral valvuloplasty by a single surgeon between February 1972
and April 2008 and were retrospectively reviewed for short- and long-term results. Overall mean age was 60.3
 13.7 years, and 57% were male. The cause was rheumatic in 193 patients, myxomatous in 1042 patients,
and ischemic and nonischemic functional mitral regurgitation in 236 patients. Ring annuloplasty was performed
in 1306 patients (87%). Commissurotomy was the primary repair for rheumatic valves, posterior leaflet resection
and reconstruction was the most common repair for myxomatous valves (527/1042 [51%]), and ring reduction
annuloplasty was the primary operation for functional mitral regurgitation.
Results: The 30-day mortality was 19 of 1503 patients (1.3%) and significantly higher in the functional mitral
regurgitation group (11/236 patients, 4.7% vs 0.5% in the rheumatic group and 0.6% in the myxomatous group,
P<.01). The 10-, 20-, and 30-year survivals were similar for the rheumatic and myxomatous groups (77%, 56%,
and 39% vs 79%, 62%, and 52%, respectively) but significantly less for the functional mitral regurgitation group
(44%, 4%, and 0%, respectively, log-rank P<.0001). The 10- and 20-year freedom from reoperation rates were
significantly better for the myxomatous group than for the rheumatic group (90% and 82% vs 66% and 34%,
log-rank P< .0001), with a 30-year freedom from reoperation of only 10% for rheumatic repair. In the myxo-
matous group, freedom from reoperation was lower in patients with anterior leaflet pathology (P ¼ .0008).
Conclusion: Follow-up data to 36 years demonstrate that cause strongly determines survival and durability of
mitral valvuloplasty; patients with rheumatic valve disease who survive more than 20 years require reoperation,
whereas functional mitral regurgitation carries the highest short- and long-term mortality rates and lowest free-
dom from reoperation. Mitral valvuloplasty for myxomatous valves demonstrates the longest durability, with
many patients free from reoperation at 30 years. (J Thorac Cardiovasc Surg 2010;139:76-84)Mitral valvuloplasty (MVP) is one of the oldest operations in
cardiac surgery. The first successful MVP operation was
performed at Brigham and Women’s Hospital by Elliot
Cutler in 1923.1 Harken and colleagues2 followed Cutler’s
lead, performing a series of closed MVPs beginning in
1948. Lillehei and colleagues3,4 made early contributions
to the understanding of the importance of the subvalvar
apparatus to ventricular performance in the late 1950s, lead-
ing to progressive efforts in valve repair. Modern MVP on
cardiopulmonary bypass (CPB) began at Brigham and
Women’s Hospital in 1972, and given the diverse repairable
mitral valve (MV) pathology over the years, we sought to
evaluate the long-term performance of mitral repair strate-
gies among different MV disease causes to compare and
contrast long-term survival and repair durability.righam and Women’s Hospital, Harvard Medical School, Boston, Mass.
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The Journal of Thoracic and Cardiovascular SurgeMATERIALS AND METHODS
By using an institutional review board-approved protocol, all MVPs per-
formed by a single surgeon (L.H.C.) through April 2008 were identified and
collected on a Microsoft Excel spreadsheet (Microsoft Corp, Redmond,
Wash). Inclusion criteria were first-time MVP operations performed on
CPB. Complex congenital lesions affecting the MV (partial and complete
atrioventricular canal, idiopathic hypertrophic subaortic stenosis) were
excluded. A small group of patients (<10) who underwent a feasibility study
with ‘‘robotic-assisted’’ MVP were also excluded because we wanted to
evaluate the long-term outcomes of standard approaches. Patients were
not excluded if concomitant other cardiac procedures were performed dur-
ing MVP.
All available operative and postoperative follow-up data were re-
viewed, and long-term follow-up was obtained by searching local
electronic health records, office charts, cardiology office follow-up
visits, mail surveys, and telephone follow-ups. Vitality statistics for
all patients were doubly verified using the website of the United
Stated Social Security Death Index. Death was categorized as either
30-day or late mortality, whereas MV reoperation was any MV pro-
cedure performed after exiting the operating room on conclusion of
the index repair. All echocardiographic data regarding valvar
regurgitation were verified on the official study report and coded on
a scale of 0 to 4 (0 ¼ none, 1 ¼ trivial, 2 ¼ mild, 3 ¼ moderate,
and 4 ¼ severe) with decimals used to code in-between qualitative de-
scriptions. Statistical analysis was performed with SAS (SAS Institute,
Inc, Carey, NC). All categoric data are expressed as mean (median
sometimes also given as indicated)  standard deviation with 25%ry c January 2010
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass graft
CPB ¼ cardiopulmonary bypass
ETE ¼ edge-to-edge
FMR ¼ functional mitral regurgitation
IQR ¼ interquartile range
MV ¼ mitral valve
MVP ¼ mitral valvuloplasty
SAM ¼ systolic anterior motion
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ysis is described according to methodology. All long-term reoperation
data are reported using actuarial Kaplan–Meier analysis for compari-
son by log-rank analysis. All long-term survival data are presented
as a Cox proportional hazard curve.RESULTS
Therewere 1503 consecutiveMVPs performed by a single
surgeon from February 23, 1972, to April 30, 2008. Overall,
there were 858 men (57%) and 645 women (43%) with
a mean age of 60.3  13.7 years (interquartile range
[IQR], 51–71). Cause of MV disease was myxomatous in
1042 patients, ischemic in 236 patients, and nonischemic
functional mitral regurgitation (FMR) and rheumatic in
193 patients (Table 1). The first 34 patients in the series
had rheumatic MV disease, and the first myxomatous valve
was repaired on September 29, 1976. The first repair of is-
chemic FMR occurred on June 18, 1981, using a Carpentier
(Edwards Lifesciences, Irvine, Calif) ring remodeling annu-
loplasty with a concomitant 4-vessel coronary artery bypass
graft (CABG).
First-time MV repair was done as a reoperation in 57
patients (3.8%), including 36 patients with previous
CABG (2.4%), 6 patients (0.4%) with previous CABG
and aortic valve replacement (AVR), 6 patients (0.5%)
with previous AVR, and 6 patients (0.5%) with previous
closed MV commissurotomy. Incision types included full
sternotomy in 861 patients (57%), right thoracotomy in 15
patients (1%), right parasternal in 134 patients (9%), and
hemisternotomy in 493 patients (33%); the differential use
of incision types per decade is illustrated in Figure 1. Of
the minimally invasive incisions, the right parasternal ap-
proach never required conversion but was ultimately aban-TABLE 1. Cause and basic demographics of the three major etiologic subty
Cause n Male (%) Age (y) MV area (cm2)
Rheumatic 193 28 (15%) 54  15 1.2  0.4
Myxomatous 1042 692 (66%) 59  13 —
FMR 236 123 (52%) 69  10 —
MV, Mitral valve; MR, mitral regurgitation; FMR, functional mitral regurgitation.
The Journal of Thoracic and Cdoned because of concerns for late lung herniation. The
hemisternotomy approach was converted to full sternotomy
6 times (6/493, 1.2%) between 2001 and 2007 because of
the inability to defibrillate in 2 cases, poor exposure in 3
cases, and an acute dissection of the ascending aorta in 1
case.
Ring annuloplasty was performed as part of MVP in 1306
patients (87%) and was increasingly more common after the
first decade, once annuloplasty rings became widely avail-
able; only 6 rings were implanted in 99 consecutive repairs
from 1972 to 1984, after which 1300 rings were implanted in
the next 1404 patients. Implants included 9 different ring
designs over 36 years, the most common of which was the
Cosgrove-Edwards ring (Edwards Lifesciences) (Table 2).
Leaflet repair techniques were performed with principles
originally reported by Carpentier5 and Duran and col-
leagues,6 but several simplified modifications based on these
principles were increasingly used.7,8 Intraoperative transeso-
phageal echocardiography has been used routinely for intra-
operative assessment of MV repair since 1990. On the basis
of unsatisfactory transesophageal echocardiogram findings,
a second crossclamp application to adjust MVP was neces-
sary in 24 patients (1.6%), all resulting in satisfactory repair.
Concomitant procedures were performed in 609 of 1503 pa-
tients: 248 CABG procedures (17%) and 361 other proce-
dures (24%), with 88 patients undergoing CABG and
other procedures.
The overall 30-day mortality was 1.3% (19/1503).
Although a ‘‘decade’’ effect has been described for large
groups of patients undergoing cardiovascular operation
over several decades, we did not identify such a phenome-
non; the operative mortality rate was 0% (0/55) in the
1970s, 1.8% (3/166) in the 1980s, 1.4% (7/488) in the
1990s, and 1.1% (9/794) in the 2000s (chi-square,
P ¼ .97). The overall mean hospital stay for the entire
series was 7.6  7.6 days (IQR, 5–8), and there was no sta-
tistical significance in hospital stay per decade (analysis of
variance, P ¼ .1704). Among patients with myxomatous
disease, rheumatic disease, and FMR, definitive long-
term survival data were available for analysis in 1432 of
1465 patients (98%) up to 36 postoperative years (total
10,390 patient years), and definitive reoperation data
were available for analysis in 1214 of 1465 patients
(83%) up to 30 postoperative years (total 6249 patient
years). These data are presented below in time-related anal-
ysis with numbers at risk provided in all cases.pes of 1503 patients undergoing mitral valve repair from 1972 to 2008
MV gradient (mm Hg) % Ejection fraction % Severe MR
12.9  9.7 58  10 25%
— 61  9 84%
— 43  13 62%
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TABLE 2. Ring annuloplasty implantation types used in 1503 patients
undergoing mitral valve repair between 1972 and 2008
MV ring type n (%) First implant
None 197 (13%) 2/23/1972
Carpentier-Edwards (Edwards
Lifesciences, Irvine, Calif)
49 (3%) 9/29/1976
Duran (Medtronic Inc,
Minneapolis, Minn)
178 (12%) 12/23/1985
St Jude Bi-Flex (St Jude
Medical, St Paul, Minn)
1 (1%) 9/19/1991
Cosgrove-Edwards (Edwards
Lifesciences)
1023 (68%) 5/17/1994
Pericardium (hand
constructed)
2 (1%) 3/9/1998
Medtronic Future GC
(Medtronic Inc)
8 (1%) 2/20/2003
Colvin-Galloway (Medtronic
Inc)
1 (1%) 6/14/2004
Carpentier-Edwards Physio
(Edwards Lifesciences)
25 (2%) 6/8/2005
GeoForm (Edwards
Lifesciences)
7 (1%) 6/8/2006
Unknown 12 (1%) —
MV, Mitral valve. Each ring is listed with its first implant date.
FIGURE 1. Relative incision use for 1503 patients undergoing MV repair
between 1972 and 2008. There were 861 full sternotomies (57%), 493
hemisternotomies (33%), 134 right parasternal incisions (9%), and 15 right
thoracotomies (1%).
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Rheumatic valve disease in 193 patients was repaired over
4 decades; analysis was possible in 187 patients (Table 1).
These patients were significantly younger than those with
myxomatous valve disease (P < .0001) and FMR (P <
.0001, paired t test), and most were female (85%) with pre-
served ejection fraction (57.9%  10.1%; IQR, 52.9%–
65%; Table 1). Variable combinations of echocardiogram
and catheterization data were used in preoperative decision
making; the mean preoperative MV area was 1.2  0.4
cm2 with a mean gradient of 12.9 9.7 mm Hg, with severe
MR present in 25% of the preoperative studies (Table 1).
Six patients with rheumatic valve disease had undergone
closed MV commissurotomy by Harken and colleagues2
between 1955 and 1972, and 1 patient had undergone
previous AVR.
CPB time was 67.1  29.5 minutes (IQR, 42–90), and
aortic crossclamp time was 50.1  27.4 minutes (IQR,
23–69). Repair consisted mainly of unilateral and bilateral
commissurotomy with variable extension into the subvalvar
apparatus. Ring annuloplasty was not used in 126 of 193
patients (67.4%); 61 rings were implanted, including a Car-
pentier ring in 14 patients, a Duran ring (Medtronic Inc,
Minneapolis, Minn) in 5 patients, and a Cosgrove ring in
42 patients. The mean size for the 61 implanted rings was
30  2.9 mm (median, 30 mm; IQR, 28–32). No patient re-
quired a second CPB or crossclamp time. Concomitant pro-
cedures were performed in 57 of 187 patients (31%),
including 12 CABGs and 52 other cardiac procedures (eg,
other valve, arrhythmia procedures). The 30-day mortality
for rheumatic repair was 0.5% (1/187 patients) with a hospi-
tal stay of 8.3  4.4 days (IQR, 6–90). The 10-, 20-, and
30-year survivals were 77%, 56%, and 39%, respectively
(Figure 2), and freedoms from MV reoperation were 66%,
34%, and 10% at 10, 20, and 30 years, respectively (Figure 3).78 The Journal of Thoracic and Cardiovascular SurgeResults of Repair for Myxomatous Valve Disease
As seen in Table 1, patients with myxomatous disease
were older than patients with rheumatic disease (P <
.0001) and younger than those with FMR (P<.0001, paired
t test), were more often male (66%), had largely preserved
ejection fraction (mean, 61.4%  8.7%; IQR, 58%–
65%), and had moderate to severe MR with MR graded as
severe in 84% (Table 3). Intraoperative inspection and de-
scription described leaflet involvement as posterior only in
683 patients (66%) and involving the anterior leaflet in
338 patients (32%); of the latter, 271 patients had bileaflet
involvement and 67 patients had isolated anterior leaflet in-
volvement. In 7 patients, MV repair was performed as a car-
diac reoperation, including 4 previous CABGs, 2 previous
AVRs, and 1 previous composite valve graft replacement
of an ascending aortic aneurysm.
Mean CPB time was 112  31 minutes (IQR, 90–128),
and mean aortic crossclamp time was 78  20 minutes
(IQR, 65–90). Ring annuloplasty was used in the majority
of myxomatous repairs (987/1042, 95%), including
Cosgrove (n ¼ 820), Duran (n ¼ 142), and Carpentier
(n ¼ 20) rings with a mean size of 33  3.7 mm (IQR,
30–36). In terms of leaflet techniques, we identified 97 dif-
ferent repair combinations with posterior leaflet resection
and commissuroplasty making up the most common build-
ing blocks of repair (Table 4). Although many patients
with isolated anterior leaflet pathology (47/67, 70%) under-
went repairs involving the anterior leaflet, 20 patients did not
(17 with only commissuroplasty and 3 with only ring im-
plantation; Table 4). The most common procedure forry c January 2010
FIGURE 2. Cox proportional hazard model of long-term survival afterMV repair for rheumatic (red), myxomatous (green), and ischemic/nonischemic FMR
(blue) disease to 30 years postoperatively. FMR, Functional mitral regurgitation.
TABLE 3. Precise repair combinations performed most frequently
(20) in 1042 patients undergoing repair of myxomatous mitral
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repair only (129/271, 48%), whereas posterior repair plus
edge-to-edge (ETE) repair was used after 1999 (62/271,
23%), as we previously reported as part of our strategy to
avoid systolic anterior motion (SAM) (Table 4). Only 67 pa-
tients with bileaflet involvement (25%) were thought to re-
quire a combined posterior and anterior leaflet repair, and the
majority of these were earlier in the series. There were 123
concomitant CABGs (12%) and 174 other cardiac proce-
dures (17%), with 22 patients undergoing both CABG and
other procedures in addition to MVP.
Twenty-two patients with myxomatous disease (22/1042,
2.1%) required a second CPB and crossclamp application
for persistent MR, mitral stenosis, or SAM, leaving the
patient with an acceptable MVP result in each case. All other
patients left the operating room with no or trace MR and an
acceptable gradient. Significant mitral stenosis was detected
in 4 patients (0.4%) and was treated in each instance by
removal of a previously placed ETE stitch. Significant resid-
ual MR was found in 6 patients (0.6%), 3 of whom had leaf-
let tethering from a portion of the new repair: The anterior
leaflet polytetrafluoroethylene (Gore-Tex; WL Gore &
Associates Inc, Newark, Del) neochords were too short inFIGURE 3. Kaplan–Meier long-term freedom from mitral reoperation
after repair for rheumatic MV disease to 30 years postoperatively.
The Journal of Thoracic and C2 patients, and an anterolateral commissuroplasty tethered
the commissure open in 1 patient. All 3 patients responded
to removal of the offending suture. The addition of an
ETE repair, an additional commissuroplasty stitch, and a re-
pair of a dehisced P2 reconstruction treated the remaining 3
patients. Severe post-bypass SAM was detected and surgi-
cally treated in 12 patients (1.2%), with no case occurring
since January of 2006, corresponding to our publication
for the indications of prophylactic ETE suture application
in cases with high SAM potential.9
The 30-day mortality for myxomatous repair was 0.6%
(6/1042 patients) and not significantly different from those
with rheumatic disease (P ¼ .95). The 10-, 20-, and 30-
year survivals were 79%, 62%, and 52%, respectively (Fig-
ure 2), and the freedoms from reoperation at 10 and 20 years
were 90% and 82%, respectively, significantly better than
for rheumatic valve disease (Figure 4, log-rank P <
.0001). Figure 5 demonstrates differential freedom from
MV reoperation based on posterior leaflet involvementvalve disease between 1972 and 2008
Repair technique n (%)
Posterior leaflet resection with reconstruction 527 (51%)
Commissuroplasty 3 1 52 (5%)
Posterior leaflet resection with reconstruction,
commissuroplasty 3 1
49 (5%)
Posterior leaflet resection with reconstruction,
Alfieri stitch
40 (4%)
Posterior leaflet imbrication (‘‘fold-o-plasty’’) 37 (4%)
Posterior leaflet resection with reconstruction,
de´bridement of MAC
26 (3%)
Posterior leaflet resection with reconstruction,
commissuroplasty 3 2
21 (2%)
MAC,Medial arterial calcification. Ring implantation accompanied 95% (987/1042).
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FIGURE 5. Differential Kaplan–Meier actuarial freedom from MV reop-
eration according to valves with posterior leaflet only pathology (black,
n ¼ 683) versus valves with anterior leaflet pathology (grey, n ¼ 338) to
22 years postoperatively.
TABLE 4. Repairs performed in 338 patients with myxomatous
disease with anterior leaflet involvement between 1972 and 2008
Bileaflet pathology n ¼ 271 (80%)
Posterior repair only (including commissuroplasty) 129
Posterior repairþAlfieri 62
Posterior repairþanterior resection 25
Posterior repairþpolytetrafluoroethylene (Gore-Tex;
WL Gore & Associates Inc, Newark, Del) artificial
chords
25
Posterior repairþchordal shortening 15
Other 15
Anterior leaflet pathology n ¼ 67 (20%)
Commissuroplasty only 17 (25%)
Ring only 3 (5%)
Anterior leaflet repairs 47 (70%)
Artificial polytetrafluoroethylene (Gore-Tex)
chords (6 with commissuroplasty, 2 with small
anterior resection)
18
Alfieri stitch (1 with commissuroplasty, 1 with
anterior perforation closure)
13
Anterior leaflet resection with reconstruction only 9
Other 7
These repairs were combined with ring implantation in 322 of 338 patients (95%).
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20-year freedoms from reoperation were higher for posterior
leaflet only (93% and 88% vs 84% and 74%, respectively,
log-rank P ¼ .0008).
Durability of repair was further assessed by evaluation of
the last known postoperative echocardiogram. Of 1042
patients, 62 had reoperation such that assessment of post-
repair by echocardiography was possible in 980. The last
available echocardiogram was located for 604 of these
patients, with studies extending to 21.3 years postopera-
tively (2419 patient years), whereas extremely wide varia-
tion in cardiology patterns of echocardiogram attainment
resulted in a mean time from surgery to last echocardiogram
of only 4  3.5 years. Studies demonstrated severe MR in 5
patients (0.8%), moderate to severe MR in 6 patients (1%),
and moderate MR in 49 patients (8%). The incidence of sig-
nificant mitral stenosis on postoperative echocardiogramFIGURE 4. Kaplan–Meier actuarial freedom from MV reoperation after
repair for myxomatous MV disease to 22 years postoperatively.
80 The Journal of Thoracic and Cardiovascular Surgewas low (9/604 patients, 1.5%); 6 cases were moderate
(1%), 2 cases were moderate to severe (0.3%), and 1 case
was severe (0.2%).Results of Repair for Ischemic and Nonischemic
Functional Mitral Regurgitation
Since the first repair of ischemic FMR in 1981, referral for
repair of ischemic and nonischemic functional regurgitation
has increased to 236 patients with analysis possible in all
patients. Compared with patients with rheumatic (P <
.0001) and myxomatous disease (P< .0001, paired t test),
this cohort is significantly more advanced in age (mean,
69  10 years; IQR, 63–77). Consistent with current under-
standing of the cause of FMR, there was a highly statistically
significant correlation with the degree of cardiac dysfunction
in this group as reflected in ejection fraction (mean, 43% 
13%; IQR, 35%–55%; P< .0001 vs rheumatic and myxo-
matous by paired t test). All had moderate to severe MR,
with severe MR noted in 62% of preoperative studies. Pre-
vious cardiac operation was more predominant in this group,
with 43 of 236 patients (18%) having MV repair done as
a reoperation, including 32 previous CABGs, 6 previous
CABGs and AVRs, and 3 previous AVRs.
Mean CPB time was 109  32 minutes (IQR, 90–120),
and mean aortic crossclamp time was 75  24 minutes
(IQR, 59–90). Repair included ring reduction annuloplasty
in all patients. Although the flexible Cosgrove (n ¼ 146)
and Duran (n ¼ 26) rings were most commonly implanted
in patients earlier in the series, we now primarily use rings
more uniquely suited for FMR (24 Carpentier-Edwards
Physio [Edwards Lifesciences], 7 Geoform [Edwards Life-
sciences], and 7 Medtronic Future GC rings). In comparison
with the other causes, undersized rings were used with a me-
dian implant size of 28  2.6 mm (IQR, 28–30), which is
significantly smaller than those used in the myxomatous
group (P< .0001). In sharp contrast with the other groups,
182 of 236 patients (77%) underwent concomitant proce-
dures that included 106 CABGs and 120 other cardiacry c January 2010
DiBardino et al Acquired Cardiovascular Diseaseprocedures. The 30-day mortality for FMR was significantly
higher than in the other groups (n¼ 11, 4.7%; P<.0001 vs
myxomatous and P ¼ .01 vs rheumatic, chi-square). The
10-, 20-, and 30-year survivals of 44%, 4%, and 0%, re-
spectively, were significantly lower than the other cohorts
(Figure 2, log-rank P< .0001), whereas the freedom from
MV reoperation was only 63% at 10 years (Figure 6).A
C
DDISCUSSION
Data from the Framingham study showed that MV pro-
lapse is among the most common cardiovascular abnormal-
ities affecting the general population (2.5% of men and
7.6% of woman) and certainly the most common human
heart valve abnormality.10 Although progression to severe
MR is an uncommon complication overall, the prevalence
of prolapse in the community assures its place as the most
common cause of MR in North America. Rheumatic MV
disease remains a common condition in Third World coun-
tries, and data regarding the durability of repair remain im-
portant for surgeons worldwide. FMR is increasingly
recognized as a harbinger of poor long-term outcomes.11
Results of MV surgery up to 29 years postoperatively
have been reported. Dr Carpentier’s series of rheumatic
valve repair demonstrated survival of 89%  19% at 10
years and 82% 18% at 20 years with freedom from reop-
eration of 55% 25% at 20 years.12 Our results are similar
given that the Carpentier series was for isolatedMR only and
excluded patients with associated aortic valve disease and
coronary artery disease; these patients were not excluded
from our study. This report also shows that at 30 years,
only 10% of patients with rheumatic cause remain free of re-
operation. Carpentier reported updated long-term results for
degenerative valve disease for a total of 2273 patient years of
follow-up giving a 20-year survival of 48% and freedom
from reoperation between 83% and 92%, depending on
the presence of anterior leaflet involvement.13 As in the
rheumatic series, these data excluded associated ‘‘cardiacFIGURE 6. Kaplan–Meier actuarial freedom from MR reoperation after
repair of FMR up to 12 years postoperatively. MV, Mitral valve.
The Journal of Thoracic and Cor vascular procedures’’ and ischemic heart disease; we
have included both and have found comparable 20-year sur-
vival and durability.
Patients with coronary artery disease were included in the
long-term Mayo Clinic results for myxomatous disease,14
with survival of MV replacement inferior to repair of ante-
rior or posterior leaflet pathology; despite a higher reopera-
tion rate for anterior versus posterior repairs, the overall
reoperation rate for MV replacement was not different for
either anterior or posterior repair. A later update from the
same authors reported a subset analysis in elderly patients
and confirmed that restoration of life expectancy is similar
in the elderly and the young and that recent survival
improvement does benefit elderly patients who should also
be considered for repair.15 We agree that all patients should
be offered repair on the basis of valve morphology, not
patient age.16
Repair of the myxomatous MV is a durable operation. An
annuloplasty ring is essential for repair to remodel the
annulus and stabilize the repair for long-term durability.
An earlier analysis from Brigham and Women’s Hospital
confirmed markedly inferior results of freedom from
progression of myxomatous disease without ring placement
(67% 12% at only 5 years).17 This has been confirmed in
many large series and remains a universally adapted tenet of
MV repair at this time. David and colleagues18 discussed
that repairs without rings resulted in larger MV area but
reiterated Carpentier’s philosophy that an MV ring converts
an anatomically bicuspid valve to a functional monocuspid
valve with little posterior valve leaflet movement. David
and colleagues did not find a difference in MV area between
the rigid Carpentier ring and the flexible Duran ring, consis-
tent with our previous observations that MVA is larger with
no ring but not different between rigid and flexible rings.7 It
has been demonstrated that the human MV is dynamic
throughout the cardiac cycle (decreasing its annular circum-
ference and area in systole) and that this geometry is pre-
served with the use of a flexible ring.19 David and
colleagues20 and Okada and colleagues21 also reported evi-
dence of superior early left ventricular function with flexible
rings, demonstrating better diastolic flow through the MV
with exercise. This remains highly controversial with animal
data from Stanford contradicting both notions (left ventricu-
lar performance in dogs and preservation of geometry in
sheep).22,23
Freedom from reoperation for anterior leaflet repair is in-
ferior to that of a posterior repair. There is little question that
P2 leaflet prolapse treated with posterior resection and annu-
loplasty is superior to the repairs currently performed on the
anterior leaflet.24,25 Commonly used anterior repair tech-
niques include chordal shortening, commissuroplasty, artifi-
cial polytetrafluoroethylene (Gore-Tex) cord placement, and
Alfieri ETE repair. Gillinov and colleagues24 reported
chordal shortening as a significant predictor of poor MVPardiovascular Surgery c Volume 139, Number 1 81
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with isolated anterior repair (89% success at 10 years).25
Despite a higher freedom from reoperation rate than reported
previously, 11% of patients had return of 3þ or 4 þMR
within 1 year of repair. Our data confirm these findings,
and this remains a continuing challenge. We have used
ETE repair for isolated A2 prolapse (including a ring annu-
loplasty) and noted mid-term results similar to those
reported by Alfieri and colleagues. We have reported excel-
lent results when the same technique is used for the preven-
tion of SAM (detected pre-bypass or based on operative
findings) but confirm poor results when it is used as a ‘‘bail-
out’’ procedure for a failed complex MVP.9
FMR continues to be an increasingly studied and debated
indication for MVP. The somewhat historical nature of this
series (with the first ischemic valve repair in 1981) is
reflected in that the majority of patients had flexible,
C-shaped MV rings implanted, and this may be an important
reason for our significantly lower freedom from MV reoper-
ation at 10 years. The introduction of the newer generation of
saddle-shaped rigid and semi-rigid remodeling rings26 may
improve on these results, or perhaps alternate technology,
such as described by Kron and colleagues,27 will prevent
recurrent MR from progressive left ventricular remodeling.
For incision use, we have pursued minimally invasive
approaches for MVP since 1996 and have reported compa-
rable results to traditional sternotomy.28,29 As we recently
reported,29 the lower hemisternotomy continues to be our
favored approach with no difference in outcomes for equiv-
alent patients undergoing sternotomy. Although the thora-
cotomy approach is not primarily used, we have reported
this to be an excellent alternative in patients with patent
grafts from CABG surgery, and it will continue to become
an important incision as laparoscopic and robotic repair
are further considered for MVP.30CONCLUSIONS
The long-term results of MVP for 3 causes indicate that
repair of myxomatous disease is long-lasting and should
stimulate earlier referrals under the new guidelines of the
American Heart Association and American College of Car-
diology.31 Although rheumatic disease is repairable, virtu-
ally all patients who survive long enough will require
reoperation. Repair results for ischemic and nonischemic
FMR have been less than effective but are promising with
further maturation of technology.References
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Dr D. Adams (New York, NY). I would like to disclose that I am
a coinventor of the Physio II (Edwards Lifesciences, Irvine, Calif)
and ischemic mitral regurgitation annuloplasty rings and have con-
sulting and royalty agreements with Edwards. Dr DiBardino, I en-
joyed your presentation and congratulate you on this effort to
provide us with the long-term follow-up of Dr Cohn’s impressive se-
ries of valve reconstruction in more than 1500 patients performed
over a 36-year period. The fact that the overall mortality in this series
averaged 1.3%with no significant difference in risk regardless of de-
cade of surgery is a testament to Dr Cohn’s skill and leadership of
one of the most outstanding programs in our specialty. My first ques-
tion relates to the completeness of your echo and reoperation follow-
up. Death is a relatively easy variable to confirm in a retrospective
analysis. Reoperations and particularly recurrence of mitral regurgi-
tation rates are more challenging. Please give us a sense of how con-
fident you are in the latter 2 event rates you present?
Dr DiBardino. Thank you, Dr Adams, for your question, and it
is nice to be graduating from a program and to see so many people
who have come before me do such great things in the field. In
regard to the completeness of the data, the survival data are 98%
complete largely because of the use of the death index, as you
acknowledge, and that is certainly the easiest hard end point to
achieve. The reoperation data are 83% complete; data for the myx-
omatous group are approximately 90% complete. The data are not
perfect, and we ran into several problems. One is, of course,
patients with international and even national referrals are tough
to investigate. The other problem is when you try to look at it
over 36 years, patients who died, say, at 20 years postoperatively
10 years ago, it might be possible to identify whether they had a re-
operation before death, and I only included patients I was 100%
sure of a hard and fixed end point. So the 83% we had is the best
we could do. I think it fairly represents the patients who were at
risk. Now, the echocardiogram data are, by far, the toughest of
the 3 to get, for many of the same reasons. The mean of the echo
data I presented here is only 4 years. The patients who are in
good functional status, it seems, don’t like to get echocardiograms
much past that, and that was a problem I ran into trying to contact
these patients and get these echo follow-ups. So that is the toughest
one to get, and it is about two thirds. We hoped to do a lot better.
Dr Adams. In your degenerative group, your most common
strategy for bileaflet prolapse is a posterior leaflet repair and ring
annuloplasty. A true anterior leaflet prolapse is actually not cor-
rected by posterior leaflet or annular surgery. Please clarify exactly
what you mean in your article by anterior leaflet involvement in
these patients. Was this assessed by preoperative echocardiography
or intraoperative valve analysis?
Dr DiBardino. That is an excellent point. The 2 superimposed
curves I showed, one is for posterior only and the other is for ante-
rior. This is by intraoperative note review. So these would be
mostly by the saline test. Yes, they reflect sort of the gestalt of
the echo in the surgeon’s mind going into the operating room and
especially the intraoperative transesophageal echocardiogram be-
fore repair, but they really were as described, by saline test, and
your point is very well taken. What this really reflects is not an
echo finding of true bileaflet prolapse but a tendency toward pro-
lapse, chordal elongation, and so forth, just as you say. And going
back so many years over so many patients, because that was theThe Journal of Thoracic and Cmost consistent way I had of identifying what the valve ‘‘looked
like,’’ it is what I went with, and that reflects, as you say, the types
of repairs the patients underwent. So that is absolutely right. This is
an intraoperative inspection.
Dr Adams. I think that will be important to clarify in your arti-
cle.
My next question is about rheumatic repair and degenerative re-
pair. The survival was similar but the reoperation rate was higher in
the rheumatic group. How do you reconcile that?
Dr DiBardino. The patients who were followed for rheumatic
disease were followed for a lot longer. The first operation for ische-
mic disease was in 1981, and the first operation for rheumatic dis-
ease was in 1972. So the follow-up is longer. Also, the reoperation
data on the patients with FMR are somewhat tainted by the fact that
many of them did not survive the first 10 years. So they fall out of
play in the Kaplan–Meier analysis.
Dr Adams. Your 10-year freedom of reoperation was only 84%
in the anterior leaflet repair subgroup. In your article, you infre-
quently use polytetrafluoroethylene neochordae or chordal transfer
or leaflet transfer, which are commonplace in most centers today.
Can you clarify your current strategy to repair anterior leaflet pro-
lapse, and do you have echo data regarding recurrence of mitral
regurgitation in this retrospective subgroup?
DrDiBardino. That is a very keen observation. You are right. In
fact, chordal transfer has never been something that Dr Cohn has
used. I can’t think of a single case identified in this series. He
just never liked it. The anterior polytetrafluoroethylene (Gore-
Tex; WL Gore & Associates Inc, Newark, Del) chordal resuspen-
sion has been used, as you say, infrequently compared with most
centers. It is not something that we prefer if we can get away with-
out doing it. Commissuroplasty is used commonly in those patients
whom we identified as having anterior prolapse toward 1 commis-
sure, and we reported in 2006 about our use of the Alfieri stitch,
mostly prophylactically when high-risk SAM is identified, but
that also fixes that kind of a problem.
In terms of isolated echo data, I do not have isolated echo data
broken down by cause.
Dr Adams. Can you clarify your current approach to patients
with ischemic mitral regurgitation given your high reoperation rates
during long-term follow-up? Have you changed your ring or repair
strategy currently or are you doing more replacements in this sub-
group?
Dr DiBardino. The answer to your question is that the ring
designs influenced what we saw over the years. When you look
at this reoperation rate, you are looking into the past in terms that
are looking at patients who received mostly C-band Cosgrove
rings. Dr Bolling is probably about to vomit here listening to
this, but it is true. And I think that the ring designs change, and
certainly we are applying more of the GeoForm and Physio rings
(Edwards Lifesciences), and hopefully you will show us some
data on the Physio II that is more promising.
Dr S. Bolling (Ann Arbor, Mich). Dan, I rise to congratulate you,
your institution, and Dr Cohn on a fantastic series. I have one
specific question. Your mortality by decade was no different, which
is a testament to the excellent care for these patients at your institu-
tion. I know your follow-up for reoperation rate is only 83% com-
plete by echo, but were you able to identify factors that influenced
your reoperation rate? Obviously our surgical techniques over theardiovascular Surgery c Volume 139, Number 1 83
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identify something, the absence of a ring or no ring or some other
factor, that led us to improve our reoperation rates?
Dr DiBardino.We at the Brigham and many others have shown
that the absence of a ring was an independent predictor of reopera-84 The Journal of Thoracic and Cardiovascular Surgetion for MV disease. That remains true, and I am in the process of
trying to perform a more formal analysis. I am trying to develop
a scoring system looking at predictors of reoperation. It is still
not ready for prime time yet. I hope to be able to speak about it
sometime in the future.ry c January 2010
